Acute myeloid leukemia: survival analysisof patients at a university hospital of Paraná

Detalhes bibliográficos
Autor(a) principal: Padilha,Sergio Lunardon
Data de Publicação: 2015
Outros Autores: Souza,Emannuely Juliani dos Santos, Matos,Marcela Coriolano Cruz, Domino,Natália Ramos
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista brasileira de hematologia e hemoterapia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842015000100021
Resumo: Objective: The aim of this study was to analyze the prognostic factors correlated with survival of patients with acute myeloid leukemia at the Hospital de Clínicas, Universidade Federal do Paraná between 2003 and 2009, as well as to investigate the clinical and epidemiological profile. Methods: The overall survival and disease-free survival were statistically evaluated using the Kaplan-Meier method, the log-rank test and multivariate evaluation by Cox regression analysis. Results: The study population was predominantly younger than 60 years old (81,6%), had intermediate cytogenetic risk (40.8%), in first complete remission after induction chemotherapy (46.9%), with a white blood count at diagnosis of less than 30 × 109 /L (57.1%) and de novo acute myeloid leukemia (62.2%). Survival curves showed that better prognosis was related to age below 60 years (median:12,4 months; p-value = 0,2227; Odds Ratio = 0,6676), good pro- gnostic cytogenetic markers (median: 97.7 months; p-value = 0.0037; Odds Ratio = 0.4239) and white blood cell count at diagnosis of less than 30 × 109 /L (median survival: 23.6 months; p- value = 0.0001; Odds Ratio = 0.3651). Regarding the French-American-British subgroups, the median overall survival was 23.5 months for M0, M1 and M2, 97.7 months for M3 and 7.4 months for M4, M5, M6, and M7 (p-value = 0.0288). Conclusion: Prognostic factors strongly influenced patient survival, as well as guided treat- ment. Moreover, these factors were consistent with the available literature adjusted for the population in question.
id ABHHTC-1_570b8980a89f40e8a54fec41d57dca9a
oai_identifier_str oai:scielo:S1516-84842015000100021
network_acronym_str ABHHTC-1
network_name_str Revista brasileira de hematologia e hemoterapia (Online)
repository_id_str
spelling Acute myeloid leukemia: survival analysisof patients at a university hospital of ParanáAcute myeloid leukemia Survival analysis PrognosisAdultCytogenetics Objective: The aim of this study was to analyze the prognostic factors correlated with survival of patients with acute myeloid leukemia at the Hospital de Clínicas, Universidade Federal do Paraná between 2003 and 2009, as well as to investigate the clinical and epidemiological profile. Methods: The overall survival and disease-free survival were statistically evaluated using the Kaplan-Meier method, the log-rank test and multivariate evaluation by Cox regression analysis. Results: The study population was predominantly younger than 60 years old (81,6%), had intermediate cytogenetic risk (40.8%), in first complete remission after induction chemotherapy (46.9%), with a white blood count at diagnosis of less than 30 × 109 /L (57.1%) and de novo acute myeloid leukemia (62.2%). Survival curves showed that better prognosis was related to age below 60 years (median:12,4 months; p-value = 0,2227; Odds Ratio = 0,6676), good pro- gnostic cytogenetic markers (median: 97.7 months; p-value = 0.0037; Odds Ratio = 0.4239) and white blood cell count at diagnosis of less than 30 × 109 /L (median survival: 23.6 months; p- value = 0.0001; Odds Ratio = 0.3651). Regarding the French-American-British subgroups, the median overall survival was 23.5 months for M0, M1 and M2, 97.7 months for M3 and 7.4 months for M4, M5, M6, and M7 (p-value = 0.0288). Conclusion: Prognostic factors strongly influenced patient survival, as well as guided treat- ment. Moreover, these factors were consistent with the available literature adjusted for the population in question. Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular2015-02-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842015000100021Revista Brasileira de Hematologia e Hemoterapia v.37 n.1 2015reponame:Revista brasileira de hematologia e hemoterapia (Online)instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)instacron:ABHHTC10.1016/j.bjhh.2014.11.008info:eu-repo/semantics/openAccessPadilha,Sergio LunardonSouza,Emannuely Juliani dos SantosMatos,Marcela Coriolano CruzDomino,Natália Ramoseng2015-09-10T00:00:00Zoai:scielo:S1516-84842015000100021Revistahttp://www.rbhh.org/pt/archivo/https://old.scielo.br/oai/scielo-oai.phpsbhh@terra.com.br||secretaria@rbhh.org1806-08701516-8484opendoar:2015-09-10T00:00Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)false
dc.title.none.fl_str_mv Acute myeloid leukemia: survival analysisof patients at a university hospital of Paraná
title Acute myeloid leukemia: survival analysisof patients at a university hospital of Paraná
spellingShingle Acute myeloid leukemia: survival analysisof patients at a university hospital of Paraná
Padilha,Sergio Lunardon
Acute myeloid leukemia Survival analysis Prognosis
Adult
Cytogenetics
title_short Acute myeloid leukemia: survival analysisof patients at a university hospital of Paraná
title_full Acute myeloid leukemia: survival analysisof patients at a university hospital of Paraná
title_fullStr Acute myeloid leukemia: survival analysisof patients at a university hospital of Paraná
title_full_unstemmed Acute myeloid leukemia: survival analysisof patients at a university hospital of Paraná
title_sort Acute myeloid leukemia: survival analysisof patients at a university hospital of Paraná
author Padilha,Sergio Lunardon
author_facet Padilha,Sergio Lunardon
Souza,Emannuely Juliani dos Santos
Matos,Marcela Coriolano Cruz
Domino,Natália Ramos
author_role author
author2 Souza,Emannuely Juliani dos Santos
Matos,Marcela Coriolano Cruz
Domino,Natália Ramos
author2_role author
author
author
dc.contributor.author.fl_str_mv Padilha,Sergio Lunardon
Souza,Emannuely Juliani dos Santos
Matos,Marcela Coriolano Cruz
Domino,Natália Ramos
dc.subject.por.fl_str_mv Acute myeloid leukemia Survival analysis Prognosis
Adult
Cytogenetics
topic Acute myeloid leukemia Survival analysis Prognosis
Adult
Cytogenetics
description Objective: The aim of this study was to analyze the prognostic factors correlated with survival of patients with acute myeloid leukemia at the Hospital de Clínicas, Universidade Federal do Paraná between 2003 and 2009, as well as to investigate the clinical and epidemiological profile. Methods: The overall survival and disease-free survival were statistically evaluated using the Kaplan-Meier method, the log-rank test and multivariate evaluation by Cox regression analysis. Results: The study population was predominantly younger than 60 years old (81,6%), had intermediate cytogenetic risk (40.8%), in first complete remission after induction chemotherapy (46.9%), with a white blood count at diagnosis of less than 30 × 109 /L (57.1%) and de novo acute myeloid leukemia (62.2%). Survival curves showed that better prognosis was related to age below 60 years (median:12,4 months; p-value = 0,2227; Odds Ratio = 0,6676), good pro- gnostic cytogenetic markers (median: 97.7 months; p-value = 0.0037; Odds Ratio = 0.4239) and white blood cell count at diagnosis of less than 30 × 109 /L (median survival: 23.6 months; p- value = 0.0001; Odds Ratio = 0.3651). Regarding the French-American-British subgroups, the median overall survival was 23.5 months for M0, M1 and M2, 97.7 months for M3 and 7.4 months for M4, M5, M6, and M7 (p-value = 0.0288). Conclusion: Prognostic factors strongly influenced patient survival, as well as guided treat- ment. Moreover, these factors were consistent with the available literature adjusted for the population in question.
publishDate 2015
dc.date.none.fl_str_mv 2015-02-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842015000100021
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842015000100021
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1016/j.bjhh.2014.11.008
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
publisher.none.fl_str_mv Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
dc.source.none.fl_str_mv Revista Brasileira de Hematologia e Hemoterapia v.37 n.1 2015
reponame:Revista brasileira de hematologia e hemoterapia (Online)
instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
instacron:ABHHTC
instname_str Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
instacron_str ABHHTC
institution ABHHTC
reponame_str Revista brasileira de hematologia e hemoterapia (Online)
collection Revista brasileira de hematologia e hemoterapia (Online)
repository.name.fl_str_mv Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
repository.mail.fl_str_mv sbhh@terra.com.br||secretaria@rbhh.org
_version_ 1754213112417878016